Table 1 Demographics and Clinical Characteristics at COVID-19 Admission of the Analytical Cohort, Northwestern Medical Group, March 2020-September 2022
|  | Non-antecedent statin user (n = 11,112) | Antecedent statin user (n = 4,412) |
|---|---|---|
Baseline variables | Â | Â |
 Age, mean (SD) | 65.56 (14.53) | 72.09 (12.62) |
 Male sex, n (%) | 5635 (50.7) | 2386 (54.1) |
 Race, n (%) |  |  |
  Asian | 338 (3.1) | 127 (2.9) |
  Black | 1468 (13.5) | 606 (13.9) |
  Multiracial1 | 198 (1.8) | 53 (1.2) |
  White | 7767 (71.3) | 3329 (76.3) |
  Other2 | 1117 (10.3) | 248 (5.7) |
  Hispanic/Latino/x ethnicity, n (%) | 1927 (17.3) | 367 (8.3) |
 County, n (%) |  |  |
  Cook | 3033 (28.4) | 1227 (28.2) |
  DeKalb | 760 (7.1) | 419 (9.6) |
  DuPage | 1835 (17.2) | 722 (16.6) |
  Kane | 1044 (9.8) | 508 (11.7) |
  Lake | 1622 (15.2) | 489 (11.2) |
  McHenry | 1629 (15.3) | 744 (17.1) |
  Others in Illinois3 | 374 (3.5) | 147 (3.4) |
  Non-Illinois Areas | 375 (3.5) | 93 (2.1) |
 Site |  |  |
  1 | 2199 (19.8) | 848 (19.2) |
  2 | 931 (8.4) | 487 (11.0) |
  3 | 1153 (10.4) | 395 (9.0) |
  4 | 718 (6.5) | 371 (8.4) |
  5 | 1488 (13.4) | 435 (9.9) |
  6 | 1221 (11.0) | 605 (13.7) |
  7 | 3212 (28.9) | 1211 (27.4) |
  8, 9 or 10 | 190 (1.7) | 60 (1.4) |
BMI ≥ 25, n (%) | 7336 (73.5) | 2908 (73.2) |
Ever smoked, n (%) | 2311 (20.8) | 662 (15.0) |
 Vaccination status on admission, n (%) |  |  |
  None | 8656 (77.9) | 2353 (53.3) |
  Incomplete | 1197 (10.8) | 960 (21.8) |
  Full | 222 (2.0) | 162 (3.7) |
  Boosted | 1037 (9.3) | 937 (21.2) |
 Quarter and Year of Admission, n (%) |  |  |
  2020 Quarter 1 | 249 (2.2) | 10 (0.2) |
  2020 Quarter 2 | 1456 (13.1) | 143 (3.2) |
  2020 Quarter 3 | 512 (4.6) | 107 (2.4) |
  2020 Quarter 4 | 2384 (21.5) | 726 (16.5) |
  2021 Quarter 1 | 978 (8.8) | 411 (9.3) |
  2021 Quarter 2 | 623 (5.6) | 194 (4.4) |
  2021 Quarter 3 | 607 (5.5) | 233 (5.3) |
  2021 Quarter 4 | 1224 (11.0) | 547 (12.4) |
  2022 Quarter 1 | 1335 (12.0) | 745 (16.9) |
  2022 Quarter 2 | 679 (6.1) | 503 (11.4) |
  2022 Quarter 3 | 835 (7.5) | 636 (14.4) |
  2022 Quarter 4 | 230 (2.1) | 157 (3.6) |
 Initial Clinical Presentation, mean (SD) |  |  |
  Heart Rate (per minute), | 90.30 (19.09) | 86.82 (19.74) |
  Respiratory rate (per minute) | 21.09 (5.76) | 20.66 (5.18) |
  Systolic blood pressure (mmHg) | 136.33 (25.19) | 137.46 (26.81) |
  Diastolic blood pressure (mmHg) | 75.10 (14.38) | 72.96 (14.80) |
  Oxygen Saturation (%) | 94.54 (6.22) | 95.08 (4.81) |
 Comorbidities at baseline, n (%) |  |  |
  Asthma | 1396 (12.6) | 825 (18.7) |
  Cancer | 3068 (27.6) | 1852 (42.0) |
  Cardiovascular disease | 5152 (46.4) | 3537 (80.2) |
  Chronic liver disease | 449 (4.0) | 243 (5.5) |
  COPD | 1195 (10.8) | 1005 (22.8) |
  Cardiovascular disease | 5152 (46.4) | 3537 (80.2) |
  Diabetes mellitus | 3356 (30.2) | 2397 (54.3) |
  HIV | 260 (2.3) | 196 (4.4) |
  Hypertension | 6902 (62.1) | 4013 (91.0) |
  Immune disorder | 1071 (9.6) | 708 (16.0) |
  Renal disease | 3227 (29.0) | 2413 (54.7) |
 Treatment during admission, n (%) |  |  |
  Bamlanivumab | 10 (0.1) | 12 (0.3) |
  Dexamethasone | 5368 (48.3) | 2120 (48.1) |
  Remdesivir | 4438 (39.9) | 2006 (45.5) |
  Sarilumab | 15 (0.1) | 1 (0.0) |
  Tocilizumbab | 512 (4.6) | 96 (2.2) |
  Steroids | 6221 (56.0) | 2532 (57.4) |
  Immune modulator4 | 401 (3.6) | 285 (6.5) |
 Outcomes |  |  |
  Composite inpatient outcome, n (%) | 2140 (19.3) | 653 (14.8) |
  ICU admission, n (%) | 2034 (18.3) | 614 (13.9) |
  Intubation, n (%) | 919 (8.3) | 226 (5.1) |
  Inpatient death, n (%) | 583 (5.2) | 196 (4.4) |
  Time to composite outcome, median [IQR] | 0.31 [0.14, 2.69] | 0.41 [0.18, 3.54] |
  Length of Stay, median [IQR] | 4.88 [2.80, 8.84] | 4.51 [2.81, 7.89] |